NOV 01, 2016 08:00 AM PDT

Development of selection strategies for Homologous Recombination Deficient (HRD) patients utilizing a Liquid Biopsy

SPONSORED BY: Epic Sciences, Epic Sciences, Epic Sciences
4 13 1166

  • VP of Translational Research, Epic Sciences
      Mark Landers has 20 years of experience developing and commercializing molecular assays to drive translational and clinical research. In his current position as VP of Translational Research at Epic Sciences, he is leading the development of assay's to characterize CTC by genotype and phenotype at the single cell level. These assays can be utilized to develop clinical tests to drive patient care decisions. Prior to his tenure at Epic Sciences, Mark was Head of R&D at AltheaDx where he developed several companion assays for targeted therapies. He has also held several senior level scientist positions in the San Diego biotech community, at companies including LifeTechnologies, Ceregene and Vical.


    DATE: November 1, 2016
    TIME: 8:00AM PT, 11:00AM ET

    Metastatic cancer is an evolving, heterogeneous disease that becomes more complex over time through the selection of sub-clonal tumor populations both in response to therapy and to disease progression. Clonal evolution necessitates evaluation of disease progression at the single cell level to better understand the heterogeneity of the disease and provide treatment options to maximize therapeutic efficacy.  To that end, we have developed a single cell liquid biopsy test to characterize patient’s CTCs for HRD status, which can be used to predict sensitivity to PARP inhibitors and/or other DNA repair targeted therapeutics. Utilizing our no cell left behind® technology, we have developed a propriety algorithm that predicts the presence of genomic scarring, a marker of HRD, based on high content image analysis of each cell’s phenotypic features. Based on the prevalence of HRD CTCs, we demonstrate the potential of the test to guide therapy.

    Show Resources
    Loading Comments...